Table 1.
Summary of demographic data and baseline characteristics (safety population)
| Parameter | ABP 501 (n=67) | Adalimumab (USA) (n=69) | Adalimumab (EU) (n=67) |
|---|---|---|---|
| Mean age, years (range) | 29.3 (19–45) | 28.7 (19–45) | 27.8 (18–44) |
| Women, n (%) | 34 (50.7) | 31 (44.9) | 22 (32.8) |
| Ethnicity, n (%) | |||
| Not Hispanic or Latino | 64 (95.5) | 65 (94.2) | 67 (100) |
| Hispanic or Latino | 3 (4.5) | 4 (5.8) | 0 |
| Race, n (%) | |||
| American Indian or Alaska Native | 0 | 2 (2.9) | 0 |
| Black or African-American | 10 (14.9) | 12 (17.4) | 0 |
| White | 55 (82.1) | 51 (73.9) | 67 (100) |
| Other | 2 (3.0) | 4 (5.8) | 0 |
| Mean weight, kg (range) | 72.9 (48.3–101.1) | 73.1 (53.1–96.7) | 75.7 (55.2–105.4) |
| Mean height, cm (range) | 170.5 (152–188) | 170.0 (155–189) | 174.0 (156–196) |
| Mean BMI, kg/m2 (range) | 24.9 (19.4–30.2) | 25.2 (19.4–29.8) | 24.9 (20.1–30.0) |
BMI, body mass index.